

23 Oct 2019 | **News**

QUOTED. 23 October 2019. Rob Kowal.

by

Medtronic said that the pivotal trial for its implantable cardioverter defibrillator without a transvenous lead has begun. See what Rob Kowal, chief medical officer for Medtronic's cardiac and heart failure business, said about it here.

"We fully believe this is not just a health benefit for individual patients but is also going to be a benefit to the economic system as well, and we will be working to collect the data to support that." – Rob Kowal, chief medical officer for cardiac and heart failure business, Medtronic

- Find out more: [Medtronic Expects EV ICD To Reduce ICD Complications, Costs](#)

[Click here](#) for a free trial of *Medtech Insight*